Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

1.25USD
15 Dec 2017
Change (% chg)

$-0.05 (-3.85%)
Prev Close
$1.30
Open
$1.30
Day's High
$1.30
Day's Low
$1.25
Volume
35,047
Avg. Vol
37,755
52-wk High
$2.92
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: --
Market Cap(Mil.): $96.98
Shares Outstanding(Mil.): 43.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

11 Dec 2017

BRIEF-Affimed reports Q3 loss per share EUR 0.18

* Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Affimed announces Q3 financial results and corporate update conference call

* Affimed announces third quarter 2017 financial results and corporate update conference call Source text for Eikon: Further company coverage:

30 Oct 2017

BRIEF-Affimed posts Q2 loss of EUR 0.18 per share

* Q2 earnings per share view EUR -0.20 -- Thomson Reuters I/B/E/S

01 Aug 2017

Earnings vs. Estimates